D.E. Shaw & Co
IMRX icon

D.E. Shaw & Co’s Immuneering IMRX Stock Holding History

D.E. Shaw & Co’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-70,127
Closed -$454K – 5527
2022
Q1 		$454K Buy
+70,127
New +$674K ﹤0.01% 4428

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's IMRX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Immuneering (IMRX) in Q2 2022, closing a stake of 70,127 shares — an estimated $454K sold.

D.E. Shaw & Co first reported a position in IMRX in Q1 2022 and held it in 1 quarter. The position peaked at $454K in Q1 2022. 37 funds tracked by Wall St. Rank hold IMRX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Immuneering position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 70,127 Immuneering shares in Q2 2022, an estimated $454K.
  • D.E. Shaw & Co first reported a position in Immuneering in Q1 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's Immuneering position peaked at $454K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Immuneering as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.